Coenzyme M
- Generic Name
- Coenzyme M
- Brand Names
- Uromitexan
- Drug Type
- Small Molecule
- Chemical Formula
- C2H6O3S2
- CAS Number
- 3375-50-6
- Unique Ingredient Identifier
- VHD28S0H7F
- Background
Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Indication
Mesna is a uroprotective agent and is used prophylactically to reduce ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Associated Conditions
- Hemorrhagic cystitis caused by cyclophosphamide, Hemorrhagic cystitis caused by ifosfamide
Hematopoietic Stem Cell Support in Vasculitis
- Conditions
- Vasculitis
- Interventions
- Biological: Autologous Stem Cell TransplantBiological: Allogeneic Stem Cell Transplant
- First Posted Date
- 2006-01-18
- Last Posted Date
- 2018-08-02
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 7
- Registration Number
- NCT00278512
- Locations
- 🇺🇸
Northwestern University, Feinberg School of Medicine, Chicago, Illinois, United States
MESNA for Prevention of Acute Deterioration of Renal Function Following Contrast Agent Application
- Conditions
- Chronic Renal InsufficiencySerum Creatinine ConcentrationContrast Media Exposition
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2005-09-22
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 106
- Registration Number
- NCT00223548
- Locations
- 🇩🇪
Division of Nephrology, University of Ulm, Ulm, Germany
Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas
- Conditions
- NeuroblastomaEwings SarcomaNon-rhabdomyosarcoma Soft Tissue Sarcoma
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2009-11-01
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00165139
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
- Conditions
- Burkitt LymphomaNon-Hodgkins LymphomaAtypical Burkitt Lymphoma
- Interventions
- First Posted Date
- 2005-08-03
- Last Posted Date
- 2013-05-23
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 10
- Registration Number
- NCT00126191
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer
- Conditions
- Kidney Neoplasms
- First Posted Date
- 2004-09-13
- Last Posted Date
- 2012-10-26
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3
- Registration Number
- NCT00091611
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Chemotherapy Plus Radiation Therapy Followed by Surgery in Treating Patients With Soft Tissue Sarcoma
- Conditions
- Sarcoma
- First Posted Date
- 2004-09-02
- Last Posted Date
- 2014-01-24
- Lead Sponsor
- Radiation Therapy Oncology Group
- Registration Number
- NCT00002791
- Locations
- 🇺🇸
Veterans Affairs Medical Center - Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Veterans Affairs Outpatient Clinic - Martinez, Martinez, California, United States
🇺🇸Harbor Hospital Center, Baltimore, Maryland, United States
Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2004-08-31
- Last Posted Date
- 2014-01-10
- Lead Sponsor
- St. Louis University
- Target Recruit Count
- 50
- Registration Number
- NCT00002628
- Locations
- 🇺🇸
Methodist Hospital-Central Unit, Memphis, Tennessee, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸St. Louis University Health Sciences Center, Saint Louis, Missouri, United States
High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Poor-Prognosis Breast Cancer
- Conditions
- Breast Cancer
- First Posted Date
- 2004-08-31
- Last Posted Date
- 2010-10-01
- Lead Sponsor
- Temple University
- Registration Number
- NCT00002509
- Locations
- 🇺🇸
Temple University Cancer Center, Philadelphia, Pennsylvania, United States
Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma
- Conditions
- Neuroblastoma
- First Posted Date
- 2004-08-23
- Last Posted Date
- 2013-07-03
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT00002634
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2004-08-23
- Last Posted Date
- 2010-10-01
- Lead Sponsor
- Temple University
- Registration Number
- NCT00002510
- Locations
- 🇺🇸
Temple University Cancer Center, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.